Attached files
| file | filename |
|---|---|
| EX-10.33 - EX-10.33 - Vanda Pharmaceuticals Inc. | d97997dex1033.htm |
| EX-32.1 - EX-32.1 - Vanda Pharmaceuticals Inc. | d97997dex321.htm |
| EX-31.1 - EX-31.1 - Vanda Pharmaceuticals Inc. | d97997dex311.htm |
| EX-10.34 - EX-10.34 - Vanda Pharmaceuticals Inc. | d97997dex1034.htm |
| EX-10.35 - EX-10.35 - Vanda Pharmaceuticals Inc. | d97997dex1035.htm |
| 10-K - FORM 10-K - Vanda Pharmaceuticals Inc. | d97997d10k.htm |
| EX-31.2 - EX-31.2 - Vanda Pharmaceuticals Inc. | d97997dex312.htm |
| EX-21.1 - EX-21.1 - Vanda Pharmaceuticals Inc. | d97997dex211.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Forms S-8 (No. 333-133368, No. 333-138070, No. 333-141571, No. 333-148924, No. 333-156995, No. 333-164567, No. 333-171962, No. 333-179265, No. 333-186509, No. 333-193614, No. 333-201754, and No. 333-209144) and on Forms S-3 (No. 333-191434 and No. 333-205513) of Vanda Pharmaceuticals Inc. of our report dated February 12, 2016 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Baltimore, Maryland
February 12, 2016